Company: CMND
Filing Date: 2025-11-26
Form Type: F-1
Source: 0001213900-25-115501
Chunk: 23

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-26
Form: F-1
Chunk 23
---
 adversely affect our ability to obtain financing on acceptable terms, if at all,
and may result in the potential loss of confidence by investors, suppliers, customers and employees and fewer business development opportunities.
Additionally, the market price of the Common Shares may decline further and shareholders may lose some or all of their investment.

<div align='center'>9

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</div>

This prospectus and elsewhere, including in our
2024 Annual Report incorporated by reference herein, and other information included or incorporated by reference in this prospectus, contains
forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives
and expectations for our business operations and financial performance and condition. Any statements contained herein that are not statements
of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology
such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,”
“could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,”
“objective,” “plan,” “predict,” “potential,” “positioned,” “seek,”
“should,” “target,” “will,” “would,” and other similar expressions that are predictions
of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking
statements include, but are not limited to, statements about:

| ● | the ability of our pre-clinical and any future clinical trials to demonstrate safety and efficacy of our future product candidates, and other positive results; |

| ● | the timing and focus of our future preclinical studies and clinical trials, and the reporting of data from those studies and trials; |

| ● | the size of the market opportunity for our future product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; |

| ● | the success of competing therapies that are or may become available; |

| ● | the beneficial characteristics, safety, efficacy and therapeutic effects of our future product candidates, as well as the potential healthcare costs saved through utilizing our future product candidates; |

| ● | the ability of our future product candidates to address needs not currently addressed by the psychedelic industry; |

| ● | the ability of our future product candidates to address needs not currently addressed by the psychedelic industry; |

| ● | our ability to obtain and maintain regulatory approval of our future